Skip to content

BIOlogical treatment GRAdual Interval Longing in severe Asthma (BIO-GRAIL)

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-524741-28-00
Enrollment
142
Registered
2026-06-05
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Asthma

Brief summary

Maintained asthma control after ~1 year of study participation with at least one step of interval prolongation. Asthma control is defined as not more than one additional exacerbation compared to baseline frequency during ~1 year and a ACQ < 2.0 at the last study visit. An exacerbation is defined as an acute worsening of symptoms lasting more than 48 hours, as assessed by the treating physician.

Detailed description

Exacerbation frequency per year., Blood eosinophile count in *10^9 cells per liter, FeNO in parts per billion (ppb), Forced Expiratory Volume in 1 second (FEV1), Forced Vital Capacity (FVC), FEV1/FVC, Asthma Control Questionnaire (ACQ), Severe Asthma Questionnaire (SAQ), Sino-Nasal Outcome Test (SNOT-22), Strict asthma control after algorithm guided interval prolongation for ~1 year. Strict asthma control is defined as ΔACQ < 0.5 and control of biomarkers., Detection of respiratory viruses during asthma exacerbations by PCR on nasopharyngeal swab, Blood eosinophile count in *10^9 cells per liter during asthma exacerbations, FeNO in parts per billion (ppb) during asthma exacerbations, ACQ during asthma exacerbations, SAQ during asthma exacerbations, Dosage of Inhaled Corticosteroids (ICS), Inhaler technique, 5 – item Medication Adherence Report Scale (MARS-5)

Interventions

DRUGCINQAERO 10 mg/mL concentrate for solution for infusion
DRUGFasenra 30 mg solution for injection in pre-filled pen
DRUGTezspire 210 mg solution for injection in pre-filled pen

Sponsors

Amsterdam UMC Stichting
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Maintained asthma control after ~1 year of study participation with at least one step of interval prolongation. Asthma control is defined as not more than one additional exacerbation compared to baseline frequency during ~1 year and a ACQ < 2.0 at the last study visit. An exacerbation is defined as an acute worsening of symptoms lasting more than 48 hours, as assessed by the treating physician.

Secondary

MeasureTime frame
Exacerbation frequency per year., Blood eosinophile count in *10^9 cells per liter, FeNO in parts per billion (ppb), Forced Expiratory Volume in 1 second (FEV1), Forced Vital Capacity (FVC), FEV1/FVC, Asthma Control Questionnaire (ACQ), Severe Asthma Questionnaire (SAQ), Sino-Nasal Outcome Test (SNOT-22), Strict asthma control after algorithm guided interval prolongation for ~1 year. Strict asthma control is defined as ΔACQ < 0.5 and control of biomarkers., Detection of respiratory viruses during asthma exacerbations by PCR on nasopharyngeal swab, Blood eosinophile count in *10^9 cells per liter during asthma exacerbations, FeNO in parts per billion (ppb) during asthma exacerbations, ACQ during asthma exacerbations, SAQ during asthma exacerbations, Dosage of Inhaled Corticosteroids (ICS), Inhaler technique, 5 – item Medication Adherence Report Scale (MARS-5)

Outcome results

None listed

Source: EU CTIS · Data processed: Jun 6, 2026